This study aims the in vivo biological characterization of an innovative minocycline delivery system, based on polymethylmethacrylate bone cement. Bone cements containing 1% or 2.5% (w/w) minocycline were formulated and evaluated through solid-state characterization. Biological evaluation was conducted in vivo, within a rat model, following the subcutaneous and bone tissue implantation, and tissue implantation associated with Staphylococcus aureus is challenging. The assessment of the tissue/biomaterial interaction was conducted by histologic, histomorphometric and microtomographic techniques. Minocycline addition to the composition of the polymethylmethacrylate bone cement did not modify significantly the cement properties. Drug release profile was marked by an initial burst release followed by a low-dosage sustained release. Following the subcutaneous tissue implantation, a reduced immune-inflammatory reaction was verified, with diminished cell recruitment and a thinner fibro-connective capsule formation. Minocycline-releasing cements were found to enhance the bone-to-implant contact and bone tissue formation, following the tibial implantation. Lastly, an effective antibacterial activity was mediated by the implanted cement following the tissue challenging with S. aureus. Kinetic minocycline release profile, attained with the developed polymethylmethacrylate system, modulated adequately the in vivo biological response, lessening the immune-inflammatory activation and enhancing bone tissue formation. Also, an effective in vivo antibacterial activity was established. These findings highlight the adequacy and putative application of the developed system for orthopedic applications.
RajendraPBMathewTPAgrawalAet al.
Characteristics of associated craniofacial trauma in patients with head injuries: an experience with 100 cases. J Emerg Trauma Shock2009;
2: 89–94.
2.
GassnerRTuliTHächlOet al.
Cranio-maxillofacial trauma: a 10 year review of 9,543 cases with 21,067 injuries. J Craniomaxillofac Surg2003;
31: 51–61.
3.
MarcianiRGontyA.Principles of management of complex craniofacial trauma. J Oral Maxillofac Surg1993;
55: 535–542.
4.
EngstrandT.Biomaterials and biologics in craniofacial reconstruction.J Craniofac Surg2012;
23: 239–242.
5.
GoodgerNWangJSmagalskiGet al.
Methylmethacrylate as a space maintainer in mandibular reconstruction. J Oral Maxillofac Surg2005;
63: 1048–1051.
6.
GovilaA.Use of methyl methacrylate in bone reconstruction. Br J Plast Surg1990;
43: 210–216.
7.
SpetzgerUVougioukasVSchipperJ.Materials and techniques for osseous skull reconstruction. Minim Invasive Ther Allied Technol2010;
19: 110–121.
8.
WangLYoonDSpicerPet al.
Characterization of porous polymethylmethacrylate space maintainers for craniofacial reconstruction. J Biomed Mater Res B Res2013;
101: 813–825.
9.
NandiSMukherjeePRoySet al.
Local antibiotic delivery systems for the treatment of osteomyelitis – a review. Mater Sci Eng C2009;
29: 2478–2485.
10.
JacksonJLeungFDuncanCet al.
The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength. Drug Deliv Transl Res2011;
1: 121–131.
11.
HakeMYoungHHakDet al.
Local antibiotic therapy strategies in orthopaedic trauma: practical tips and tricks and review of the literature. Injury2015;
46: 1447–1456.
12.
DuewelhenkeNKrutOEyselP.Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother2007;
51: 54–63.
13.
RathboneCCrossJBrownKet al.
Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res2011;
29: 1070–1074.
14.
XinluanWYuxiaoLHelenaNH-Let al.
Systemic drug delivery systems for bone tissue regeneration – a mini review. Curr Pharm Des2015;
21: 1575–1583.
15.
BainSRamamurthyNImpedugliaTet al.
Tetracycline prevents cancellous bone loss and maintains near-normal rates of bone formation in streptozotocin diabetic rats. Bone1997;
21: 147–153.
16.
PayneJGolubL.Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res2011;
63: 121–129.
17.
PytlikMFolwarcznaJJaniecW.Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int2004;
75: 225–230.
18.
GomesPSFernandesMH.Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Arch Oral Biol2007;
52: 251–259.
19.
GomesPSFernandesMH.Cell-induced response by tetracyclines on human bone marrow colonized hydroxyapatite and bonelike. Acta Biomater2008;
4: 630–637.
20.
SilvaTGrenhoLBarrosJet al.
Minocycline-releasing PMMA system as a space maintainer for staged bone reconstructions – in vitro antibacterial, cytocompatibility and anti-inflammatory characterization. Biomed Mater2017;
12: 035009.
21.
MatosAGonçalvesLRijoPet al.
A novel modified acrylic bone cement matrix. A step forward on antibiotic delivery against multiresistant bacteria responsible for prosthetic joint infections. Mater Sci Eng C2014;
38: 218–226.
22.
WuS.Calculation of interfacial tension in polymer systems. J Polym Sci Part C1971;
34: 19–30.
23.
MatosAPintoRBettencourtA.Easy-assessment of levofloxacin and minocycline in relevant biomimetic media by HPLC-UV analysis. J Chromatogr Sci2017;
55: 757–765.
24.
MatosARibeiroIGuedesRet al.
Key-properties outlook of a levofloxacin-loaded 645 acrylic bone cement with improved antibiotic delivery. Int J Pharm2015;
485: 317–328.
25.
GomesPSFernandesMH.Rodent models in bone-related research – the relevance of calvarial defects in the assessment of bone regeneration strategies. Lab Anim2011;
45: 14–24.
26.
GomesPZomorodianAKwiatkowskiLet al.
In vivo assessment of a new multifunctional coating architecture for improved Mg alloy biocompatibility. Biomed Mater2016;
11: 045007.
27.
DurãoSGomesPColaçoBet al.
The biomaterial-mediated healing of critical size bone defects in the ovariectomized rat. Osteoporos Int2015;
25: 1535–1545.
28.
FerreiraMRzhepishevskaOGrenhoLet al.
Levofloxacin-loaded bone cement delivery system: highly effective against intracellular bacteria and Staphylococcus aureus biofilms. Int J Pharm. 2017;
532: 241–248.
29.
FrutosGPastorJMartínezNet al.
Influence of lactose addition to gentamicin-loaded acrylic bone cement on the kinetics of release of the antibiotic and the cement properties. Acta Biomater2010;
6: 804–811.
30.
BormannNSchwabePSmithMet al.
Analysis of parameters influencing the release of antibiotics mixed with bone grafting material using a reliable mixing procedure. Bone2014;
59: 162–172.
31.
KolaczkowskaEKubesP.Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol2013;
13: 159–175.
32.
ForsgrenASchmelingDBanckG.Effect of antibiotics on chemotaxis of human polymorphonuclear leucocytes in vitro. Infection1978;
6: S102–S1S6.
33.
ParentiAIndoratoBPaccosiS.Minocycline affects human neutrophil respiratory burst and transendothelial migration. Inflamm Res2017;
66: 107–109.
34.
AkamatsuHNiwaYKurokawaIet al.
Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism. Arch Dermatol Res1991;
283: 524–528.
35.
GablerWLCH.Suppression of human neutrophil functions by tetracyclines. J Periodont Res1991;
26: 52–58.
36.
BanckGForsgrenA.Antibiotics and suppression of lymphocyte function in vitro. Antimicrob Agents Chemother1979;
16: 554–560.
37.
KloppenburgMVerweijCMiltenburgAet al.
The influence of tetracyclines on T cell activation. Clin Exp Immunol1995;
102: 635–641.
38.
TaiKIwasakiHIkegayaSet al.
Minocycline modulates cytokine and chemokine production in lipopolysaccharide-stimulated THP-1 monocytic cells by inhibiting IκB kinase α/β phosphorylation. Transl Res2013;
161: 99–109.
39.
KremlevSRobertsRPalmerC.Minocycline modulates chemokine receptors but not interleukin-10 mRNA expression in hypoxic-ischemic neonatal rat brain. J Neurosci Res2007;
85: 2450–2459.
40.
KendallRFeghali-BostwickC.Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol2014;
5: 123.
41.
MidwoodKWilliamsLSchwarzbauerJ.Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol2004;
36: 1031–1037.
42.
MutsaersSBishopJMcGroutherGet al.
Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol1997;
29: 5–17.
43.
DrygiannakisIValatasVSfakianakiOet al.
Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. J Crohns Colitis2013;
7: 286–300.
44.
SekiESchwabeR.Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology2015;
61: 1066–1079.
45.
StrieterR.What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc2008;
5: 305–310.
46.
ElAttarTLinHShultzR.Effect of minocycline on prostaglandin formation in gingival fibroblasts. J Periodont Res1988;
23: 285–286.
47.
SchneirMRamamurthyNGolubL.Minocycline-treatment of diabetic rats normalizes skin collagen production and mass: possible causative mechanisms. Matrix1990;
10: 112–123.
48.
AndersonJMRodriguezAChangD.Foreign body reaction to biomaterials. Semin Immunol2008;
20: 86–100.
49.
BastosLMerloLRochaLet al.
Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol2007;
576: 171–179.
50.
RolfeBMooneyJZhangBet al.The fibrotic response to implanted biomaterials: implications for tissue engineering. In: EberliD (ed) Regenerative medicine and tissue engineering – cells and biomaterials.
Croatia:
InTech, 2011, pp.551–568.
51.
KauppinenASalminenAKaarnirantaK.Inflammation as a target of minocycline: special interest in the regulation of inflammasome signaling. Inflammasome2014;
1: 2–14.
52.
LiJChenJMoHet al.
Minocycline protects against NLRP3 inflammasome-induced inflammation and P53-associated apoptosis in early brain injury after subarachnoid hemorrhage. Mol Neurobiol2016;
53: 2668–2678.
53.
ChenWZhaoMZhaoSet al.
Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline. Inflamm Res2017;
66: 157–166.
54.
GuerraARoseWHemattiPet al.
Minocycline enhances the mesenchymal stromal/stem cell pro-healing phenotype in triple antimicrobial-loaded hydrogels. Acta Biomater2017;
51: 184–196.
55.
TilakaratneASooryM.An osteoblastic inflammatory redox model, using TNF-a, glucose and glucose- oxidized low- density lipoprotein: targets for minocycline. Clin Immunol Endocrine Metab Drugs2015;
2: 43–51.
56.
JayaramanPGandhimathiCVenugopalJet al.
Minocycline hydrochloride entrapped biomimetic nanofibrous substitutes for adipose-derived stem cells differentiation into osteogenesis. Regen Eng Transl Med2016;
2: 10–22.
57.
ThamAGandhimathiCPraveenaJet al.
Minocycline loaded hybrid composites nanoparticles for mesenchymal stem cells differentiation into osteogenesis. Int J Mol Sci2016;
17: 1222.
58.
ShahSTataraALamJet al.
Polymer-based local antibiotic delivery for prevention of polymicrobial infection in contaminated mandibular implants. ACS Biomater Sci Eng2016;
2: 558–566.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
